The largest database of trusted experimental protocols

8 protocols using gsk2126458

1

Immunomodulatory Compound Procurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Rapamycin (aka. Sirolimus) was purchased from LC Laboratories (Woburn, Massachusetts), GSK-2126458 and KU-0063794 were obtained from Selleck Chemicals (Houston, Texas). Fetal Calf Serum (FCS) was obtained from Gibco (Montgomery County, Maryland). Gentamicin was obtained from Biosera (Heathfield, East Sussex). IL-4 and IFN-γ ELISA kits were purchased from eBioscience (San Diego, California). All other materials such as Schneider and RPMI-1640 media were purchased from Sigma-Aldrich (Oakville, Ontario).
+ Open protocol
+ Expand
2

Evaluating PI3K/mTOR and AKT Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
The commercially available PI3K/mTOR and AKT inhibitors, GDC-0941, BKM-120, BYL-719, TGX-221, BEZ-235, GSK-2126458, and MK-2206, described in the manuscript were purchased from Selleckchem (www.selleckchem.com). The inhibitors were tested at 10 μM except GSK-2126458 that was used at 1.0 μM.
+ Open protocol
+ Expand
3

Epigenetic and Signaling Pathway Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNMT inhibitor azacytidine was purchased from Sigma (Cat. No. A2385) and dissolved in DMSO. PI3K-Akt inhibitor GSK2126458 was purchased from SelleckChem (Cat. No. S2658) and dissolved in DMSO.
+ Open protocol
+ Expand
4

mTOR Kinase Activity Assay Using TR-FRET

Check if the same lab product or an alternative is used in the 5 most similar protocols
LANCE® ultra time-resolved fluorescence resonance energy transfer (TR-FRET) assay (Invitrogen, Carlsbad, CA, USA) was used to determine the mTOR kinase activities of all the compounds following the manufacturer’s instructions, with compound GSK2126458 (Selleck, China) as positive control.39 (link) Briefly, mTOR enzyme (0.1 μg/mL, Invitrogen, Carlsbad, CA, USA), ATP (3 μmol/L (μM)), GFP-4EBP1 peptide (0.4 μM), and test compounds were diluted in kinase buffer (50 mM HEPES pH 7.5, 1 mM EGTA, 3 mmol/L (mM) MnCl2, 10 mM MgCl2, 2 mM DTT, and 0.01% Tween-20). The reaction was performed in black 384-well proxiplates (Corning, New York, NY, USA) at room temperature for 1 h, then stopped by adding EDTA to 10 mM. Tb-antiphospho-4EBP1 (Thr37/46) antibody (PerkinElmer, Fremont, CA, USA) was added to each well, and the mixture was incubated at room temperature for 30 min. Test compound concentrations were 10,000, 2500, 625, 156.25, 39.06, 9.77, 2.44, 0.61, 0.15, 0.04 and 0.01 nM. The final DMSO concentration was 1%. A Spectramax 190 reader (Molecular Devices, Valley, CA, USA) was used to measure the intensity of the light in TR-FRET mode (excitation 320 nm, emission 665 nm). All compounds were tested twice, and the results were expressed as the average IC50 (inhibitory concentration 50%) of the two experiments.
+ Open protocol
+ Expand
5

Evaluating PDGFRA Mutant Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
MCF10A cells stably expressing PDGFRA mutants (5000 cells per 100 μl) were seeded in 96-well plates in 5% serum medium without EGF/insulin. Cells were treated with DMSO or inhibitors (2.44 nM to 10 μM) for 72 h. Cell viability was determined using Presto Blue (Invitrogen) at 530 nm excitation/ 604 nm emission. Cell viability relative to DMSO treated cells was calculated. Each treatment was performed in triplicate. The IC50 was calculated with Graphpad Prism 6. Imatinib, Nilotinib, Sunitinib, Crenolanib, GSK2126458 (PI3K/mTOR inhibitor), and GSK1120212B (MEK inhibitor) were from Selleck. The inhibitors were dissolved in DMSO and stored as 10 mM aliquots at −20 °C. AZD9150 (antisense oligonucleotide against human STAT3) and the control nontargeting antisense oligonucleotide (ASO) were provided by AstraZeneca and Ionis Pharmaceuticals as 4.2 mM and 1.8 mM stock solution, respectively. The ASOs were formulated in PBS and the stock were aliquoted and stored at −20 °C.
+ Open protocol
+ Expand
6

Lung Cancer Cell Lines and Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human lung adenocarcinoma cell lines H358 and A549 were purchased from Immuno-Biological Laboratories Co. and American Type Culture Collection, respectively. The human lung adenocarcinoma cell line PC-9 was purchased from Immuno-Biological Laboratories Co. (Gunma, Japan). H358, A549, and PC-9 cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 units/mL streptomycin.
Gefitinib was obtained from AstraZeneca. Goat anti-human HGF neutralizing antibody and control goat IgG were purchased from R & D Systems. Erlotinib, PHA-665752, GSK2126458, PF04691502, AZD-8330 and TAK-733 were purchased from Selleck chemicals.
+ Open protocol
+ Expand
7

Kinase Inhibitor Library Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
A kinase inhibitor library containing 160 well-characterized kinase inhibitors was purchased from EMD Millipore. Neratinib, afatinib, PD153035, and GSK2126458 were purchased from Selleck Chem. RAD001 and GDC0980 were provided by Joseph Testa (Fox Chase Cancer Center), and BEZ235 was supplied by Timothy Yen (Fox Chase Cancer Center). The following compounds were purchased from LC Labs: bosutinib isomer, dasatinib, dovitinib, erlotinib, gefitinib, imatinib, lapatinib, masitinib, mubritinib, nilotinib, pazopanib, roscovitine, sorafenib, sunitinib, tandutinib, tofacitinib, tozasertib, vandetanib, vatalanib, and VX702. All compounds were solubilized and stored at −80°C in 100% dimethyl sulfoxide (DMSO).
+ Open protocol
+ Expand
8

Compound Library Maintenance and Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Compounds
in the DOS Informer, DOS-A, Repurposing,
and Bioactive libraries were maintained in the Broad Institute and
printed into 96- and 384-well plates using a Tecan D300e drug printer.
A subset of the repurposed compounds was purchased commercially for
validation studies: PIK-93, GSK2126458 (Omipalisib), Duvelisib (IPI-145,
INK1197), KD025 (SLx-2119), LY2784544, Palbociclib, Torin-2, AZD8186,
AT-9283, and AZD5438 (Selleckchem); ETP-45658 (R&D Systems); ETP-46464,
CP-640186, and BMS-536924 (Sigma-Aldrich); PF-03814735, TGX-221, and
Taselisib (GDC-0032) (Cayman Chemical); anandamide (VWR Scientific);
AM404 (Santa Cruz Biotech) and oleylethanolamide (Combi Blocks). Stock
solutions were prepared in DMSO and stored as per manufacturer’s
instructions.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!